# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-25-054428
**Filing Date:** 2025-6
**Character Count:** 74680
**Document Hash:** fb646f71a9596f48fcdbd9434f860cb4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-054428.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001213900-25-054428

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250613

**EFFECTIVENESS DATE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288058
- **FILM NUMBER:** 251048150

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

**As filed with the Securities and Exchange Commission on June 13, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**INMUNE BIO INC.** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **47-5205835** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> identification No.) |

---

**225 NE Mizner Blvd., Suite 640**

**Boca Raton, FL 33432**

(Address of principal executive offices) (Zip Code)

**INmune Bio Inc. 2017 Stock Incentive Plan**

**INmune Bio Inc. 2019 Stock Incentive Plan**

(Full title of the plan)

**David Moss**

**Chief Financial Officer**

**INmune Bio Inc.**

**225 NE Mizner Blvd., Suite 640**

**Boca Raton, FL 33432** 

(Name and address of agent for service)

**<u>(561) 710-0512</u>**

(Telephone number, including area code, of agent for service)

**Copies to:**

**Marc Ross, Esq.**

**Sichenzia Ross Ference Carmel LLP**

**1185 Avenue of the Americas, 31<sup>st</sup> Floor**

**New York, New York 10036**

**Phone: 212- 930-9700**

**Fax: 212-930-9725**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement also includes a prospectus (the "reoffer prospectus") prepared in accordance with General Instruction C of Form S-8 and in accordance with the requirements of Part I of Form S-3. This reoffer prospectus for shares granted under the INmune Bio Inc. 2017 Stock Incentive Plan (the "2017 Plan") and INmune Bio Inc. 2019 Stock Incentive Plan (the "2019 Plan") may be used for the reoffer and resale of shares of common stock on a continuous or delayed basis that may be deemed to be "restricted securities" and/or "control securities" within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated thereunder, that are issuable to certain of our executive officers, employees, consultants and directors identified in the reoffer prospectus. The number of shares of common stock included in the reoffer prospectus represents shares of common stock issuable to the selling stockholders pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders and does not necessarily represent a present intention to sell any or all such shares of common stock.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

This Registration Statement relates to two separate prospectuses.

<u>Section 10(a) Prospectus</u>: Items 1 and 2, from this page, and the documents incorporated by reference pursuant to Part II, Item 3 of this prospectus, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

<u>Reoffer Prospectus</u>: The material that follows Item 2, up to but not including Part II of this Registration Statement, of which the reoffer prospectus is a part, constitutes a "reoffer prospectus," prepared in accordance with the requirements of Part I of Form S-3 under the Securities Act. Pursuant to Instruction C of Form S-8, the reoffer prospectus may be used for reoffers or resales of shares of common stock which are deemed to be "control securities" or "restricted securities" under the Securities Act that have been acquired by the selling stockholders named in the reoffer prospectus.

**Item 1. Plan Information.**

INmune Bio Inc. will provide each participant (the "Recipient") with documents that contain information related to the 2017 Plan and 2019 Plan, and other information including, but not limited to, the disclosure required by Item 1 of Form S-8, which information is not filed as a part of this Registration Statement on Form S-8. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration Statement taken together constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.

**Item 2. Registrant Information and Employee Plan Annual Information.**

We will provide to each Recipient a written statement advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement and of documents required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral notice by contacting:

INmune Bio Inc.

225 NE Mizner Blvd., Suite 640

Boca Raton, FL 33432

Attention: Corporate Secretary

Telephone: (561) 710-0512

**Information required by Part I to be contained in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities Act.**

**REOFFER PROSPECTUS**

**INmune Bio Inc.** 

**3,324,550 Shares of Common Stock**

This reoffer prospectus relates to the aggregate sale of 3,324,550 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in this reoffer prospectus for their own account. Such shares have been or may be acquired in connection with 1,592,000 awards granted under the 2017 Plan) and 1,732,550 awards granted under the 2019 Plan. It is anticipated that the selling stockholders will offer shares for sale at prevailing prices on the Nasdaq Capital Market on the date of sale. We will receive no part of the proceeds from sales made under this reoffer prospectus. The selling stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with the registration and offering and not borne by the selling stockholders will be borne by us.

This reoffer prospectus has been prepared for the purposes of registering the shares under the Securities Act of 1933, as amended (the "Securities Act") to allow for future sales by selling stockholders on a continuous or delayed basis to the public without restriction.

The selling stockholders and any brokers executing selling orders on their behalf may be deemed to be "underwriters" within the meaning of the Securities Act, in which event commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.

Our common stock is quoted on the Nasdaq Capital Market under the symbol "INMB." The last reported sale price of our common stock on the Nasdaq Capital Market on June 12, 2025, was $7.92 per share.

**Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 2 of this reoffer prospectus.** 

**Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or determined if this reoffer prospectus is truthful or complete. Any representation to the contrary is a criminal offense.** 

The date of this reoffer prospectus is June 13, 2025.

**<u>**TABLE OF CONTENTS**</u>**

---

| | |
|:---|:---|
|  | **Page** |
| [Cautionary Note Regarding Forward Looking Statements](#a_001) | ii |
| [Prospectus Summary](#a_002) | 1 |
| [Risk Factors](#a_003) | 2 |
| [Determination of Offering Price](#a_004) | 3 |
| [Use of Proceeds](#a_005) | 3 |
| [Selling Stockholders](#a_006) | 3 |
| [Plan of Distribution](#a_007) | 5 |
| [Legal Matters](#a_008) | 7 |
| [Experts](#a_009) | 7 |
| [Incorporation of Certain Documents by Reference](#a_010) | 7 |
| [Disclosure of Commission Position on Indemnification For Securities Act Liabilities](#a_011) | 8 |
| [Additional Information Available to You](#a_012) | 8 |

---

NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS, OTHER THAN THOSE CONTAINED IN THIS REOFFER PROSPECTUS, IN CONNECTION WITH THE OFFERING MADE HEREBY, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OTHER PERSON. NEITHER THE DELIVERY OF THIS REOFFER PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS REOFFER PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.

i

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

Some of the statements made under "Prospectus Summary," "Risk Factors," and elsewhere in this reoffer prospectus, as well as the documents incorporated by reference herein, including in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends," or "continue," or the negative of these terms or other comparable terminology.

These forward-looking statements may include, but are not limited to, statements related to our expected business, new product introductions, results of clinical studies, expectations regarding regulatory clearance and the timing of U.S. Food and Drug Administration ("FDA") or non-U.S. filings or approvals including meetings with FDA or non-U.S. regulatory bodies, our ability to raise funds for general corporate purposes and operations, including our research activities and clinical trials, procedures and procedure adoption, future results of operations, future financial position, our ability to generate revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, the effect of recent accounting pronouncements, our anticipated cash flows, our ability to finance operations from cash flows or otherwise, and statements based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and intend to operate and our beliefs and assumptions regarding these economies and markets.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate.

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others, those factors referred to in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated by reference herein.

These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in the documents incorporated by reference herein. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this reoffer prospectus.

ii

**PROSPECTUS SUMMARY**

*This reoffer prospectus is part of the Registration Statement that we filed with the SEC. We have provided to you in this reoffer prospectus a general description of the selling stockholders and the distribution of the shares of common stock. To the extent there is a conflict between the information contained in this reoffer prospectus and any of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede the earlier statement.* 

*As permitted by the rules and regulations of the SEC, the Registration Statement of which this reoffer prospectus forms a part includes additional information not contained in this reoffer prospectus. You may read the Registration Statement and the other reports we file with the SEC at the SEC's website or at our website as described above under the heading "Incorporation of Certain Documents by Reference."* 

*In this reoffer prospectus, the "Company," "we," "us" and "our" refer to INmune Bio Inc. and its subsidiaries.*

**Company Overview**

Our objective is to develop and commercialize our product candidates to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient's disease. Innate immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where natural killer cells are impaired and facilitate a tumor's evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated in neurologic and metabolic diseases where it impairs the innate immune system. Our primary focus continues to be treatment of cancer with INKmune and treatment of Alzheimer's Disease ("AD") and Treatment Resistant Depression ("TRD") with XPro1595 ("XPro"). We have added CORDStrom, a pooled, human umbilical cord mesenchymal stem cell product to treat recessive dystrophic epidermolysis bullosa ("RDEB"), a pediatric orphan disease caused by mutations in the COL7A1 gene that results in a debilitating disease of skin blistering, dysphagia and failure to thrive with chronic wound problems that often results in fatal squamous cell carcinoma.

XPro, targets AD and TRD. XPro for AD has completed Phase I trials and a Phase II trial has completed enrollment of patients at clinical sites in the United Kingdom, European Union ("EU"), Australia and Canada. Patients are currently being treated with XPro for early AD as part of that clinical trial. TRD is being prepared for Phase II trials. We expect to start a pivotal global registration trial in patients with AD after the results of the Phase II trial have been analyzed. The INKmune program is in an open label Phase II trial in metastatic castrate resistant prostate cancer. CORDStrom for the treatment of children with RDEB has completed a pivotal blinded randomized cross-over trial. The data will be submitted for a marketing authorization by filing a biologics license application with the FDA which is anticipated in the first half of 2026. Afterwards, the company intends to file a marketing authorization application in the United Kingdom and EU.

**Corporate Information** 

Our principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432. Our telephone number is (561) 710-0512. We maintain an Internet website at www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of this reoffer prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC's website at http://www.sec.gov.

**About This Offering**

This offering relates to the resale by the selling stockholders of up to 1,592,000 and 1,732,550 shares of common stock issued or issuable upon exercise of options issued pursuant to grants made pursuant to our 2017 Plan and 2019 Plan, respectively. If, subsequent to the date of this reoffer prospectus, we grant additional shares of common stock to the selling stockholders or to other affiliates under the 2017 Plan and 2019 Plan, we may supplement this reoffer prospectus to reflect such additional shares to the selling stockholders and/or the names of such affiliates and the number of shares to be reoffered by them under the 2017 Plan and 2019 Plan. Subject to the satisfaction of any conditions to vesting of the shares of common stock offered hereby pursuant to the terms of the relevant award agreements, the selling stockholders may from time to time sell, transfer or otherwise dispose of any or all of the shares of common stock covered by this reoffer prospectus through underwriters or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents. We will not receive any proceeds from the sale of common stock by the selling stockholders. The selling stockholders will bear all sales commissions and similar expenses. We will bear all expenses of registration incurred in connection with this offering, including any other expenses incurred by us in connection with the registration and offering that are not borne by the selling stockholders.

**RISK FACTORS**

Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our most recently filed Annual Report on Form 10-K, our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we have filed or will file with the SEC.

Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and, as a result, you may lose all or part of your investment. The risks we have described also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements. See "*Cautionary Note Regarding Forward-Looking Statements*."

**DETERMINATION OF OFFERING PRICE**

The selling stockholders will determine at what price they may sell the shares of common stock offered hereby, and such sales may be made at prevailing market prices or at privately negotiated prices. See "*Plan of Distribution*" below for more information.

**USE OF PROCEEDS**

The shares of common stock offered hereby are being registered for the account of the selling stockholders named in this reoffer prospectus. All proceeds from the resale of the shares of common stock by the selling stockholders will go to the selling stockholders and we will not receive any proceeds from such resale. However, we will receive the cash exercise price if any of the selling stockholders exercise their options for common stock on a cash basis. We intend to use the net proceeds, if any, for working capital or general corporate purposes. We have agreed to pay the expenses of registration of these shares.

**SELLING STOCKHOLDERS** 

This offering relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant to the 2017 Plan and 2019 Plan. The selling stockholders may resell all, a portion, or none of the shares of common stock from time to time.

The following table sets forth, based on information provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering. Except as otherwise indicated, the selling stockholders are past or present employees, directors or consultants of the Company. The number of shares owned are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares of common stock as to which a person has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement. None of the selling stockholders is a broker-dealer or an affiliate of a broker-dealer. Percentage of ownership is based on 23,379,796 shares of common stock outstanding on May 31, 2025.

We have assumed all shares of common stock reflected on the table will be sold from time to time in the offering covered by this reoffer prospectus. Because the selling stockholders may offer all or any portion of the shares of common stock listed in the table below, no estimate can be given as to the amount of those shares of common stock covered by this reoffer prospectus that will actually be held by the selling stockholders upon the termination of the offering. Selling stockholders may choose not to sell any of the shares of common stock registered herein.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Number of Shares**<br> **Beneficially Owned Prior<br> to Offering (1)** | **Number of Shares**<br> **Beneficially Owned Prior<br> to Offering (1)** | |  | **Number of Shares <br> Beneficially Owned After<br> Offering** | **Number of Shares <br> Beneficially Owned After<br> Offering** |
| <br>**Selling Stockholder** | <br>**Position** | **Number** | **Percent (%)** | **Number of <br> Shares<br> Being**<br>**Offered** |  | **Number** | **Percent (%)** |
| Raymond J. Tesi | President, CEO and Director | 2730952 | 11.1% | 729337 | (2) | 2001615 | 8.4% |
| David Moss | CFO, Treasurer and Secretary | 2422143 | 9.9% | 734337 | (3) | 1687806 | 7.1% |
| Mark Lowdell | CSO | 2238396 | 9.3% | 580000 | (4) | 1658396 | 7.0% |
| Scott Juda | Director | 427900 | 1.8% | 231975 | (5) | 195925 | \* |
| Timothy Schroeder | Director | 408881 | 1.7% | 231975 | (6) | 176906 | \* |
| J. Kelly Ganjei | Director | 344487 | 1.5% | 231975 | (7) | 112512 | \* |
| Marcia Allen | Director | 218694 | \* | 139951 | (8) | 81850 | \* |
| Named Selling Stockholders |  | 1211346 | 5.1% | 445000 | (9) | 766346 | 3.2% |
| Total |  | 10002799 |  | 3324550 |  | 6681356 |  |

---

\* Less than 1%

(1) The securities "beneficially owned" by a person are determined in accordance with the definition of "beneficial ownership" set forth in the rules and regulations promulgated under the Exchange Act, and accordingly, may include securities owned by and for, among others, the spouse and/or minor children of an individual and any other relative who has the same home as such individual, as well as other securities as to which the individual has or shares voting or investment power or which such person has the right to acquire within 60 days of May 31, 2025, pursuant to the exercise of options, or otherwise. Beneficial ownership may be disclaimed as to certain of the securities.

(2) Includes: (a) vested options to purchase 400,000 shares of common stock exercisable by Mr. Tesi at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase 270,000 shares of common stock exercisable by Mr. Tesi at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested options to purchase 59,337 shares of common stock exercisable by Mr. Tesi at an exercise price of $24.82 per share pursuant to the 2019 Plan.

(3) Includes: (a) vested options to purchase 400,000 shares of common stock exercisable by Mr. Moss at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase 59,337 shares of common stock exercisable by Mr. Moss at an exercise price of $24.82 per share pursuant to the 2017 Plan; and (c) vested options to purchase 275,000 shares of common stock exercisable by Mr. Moss at an exercise price of $3.91 per share pursuant to the 2019 Plan.

(4) Includes: (a) vested options to purchase 400,000 shares of common stock exercisable by Mr. Lowdell at an exercise price of $7.80 per share pursuant to the 2017 Plan; and (b) vested options to purchase 180,000 shares of common stock exercisable by Mr. Lowdell at an exercise price of $3.91 per share pursuant to the 2019 Plan.

(5) Includes (a) vested options to purchase 108,000 shares of common stock exercisable by Mr. Juda at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase 108,000 shares of common stock exercisable by Mr. Juda at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested options to purchase 15,975 shares of common stock exercisable by Mr. Juda at an exercise price of $24.82 per share pursuant to the 2019 Plan.

(6) Includes: (a) vested options to purchase 108,000 shares of common stock exercisable by Mr. Schroeder at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase 108,000 shares of common stock exercisable by Mr. Schroeder at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested options to purchase 15,975 shares of common stock exercisable by Mr. Schroeder at an exercise price of $24.82 per share pursuant to the 2019 Plan.

(7) Includes: (a) vested options to purchase 108,000 shares of common stock exercisable by Mr. Ganjei at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase 108,000 shares of common stock exercisable by Mr. Ganjei at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested options to purchase 15,975 shares of common stock exercisable by Mr. Ganjei at an exercise price of $24.82 per share pursuant to the 2019 Plan.

(8) Includes: (a) vested options to purchase 108,000 shares of common stock exercisable by Mrs. Allen at an exercise price of $3.91 per share pursuant to the 2019 Plan; (b) vested options to purchase 15,975 shares of common stock exercisable by Mrs. Allen at an exercise price of $24.82 per share pursuant to the 2019 Plan; (c) options to purchase 7,313 shares of common stock exercisable by Mrs. Allen at an exercise price of $9.74 per share pursuant to the 2019 Plan of which 5,891 are exercisable; and (d) options to purchase 8,663 shares of common stock exercisable by Mrs. Allen at an exercise price of $9.74 pursuant to the 2017 Plan, of which 6,978 are exercisable.

(9) Includes the following 3 named non-affiliate persons, each of whom holds at least 1,000 Shares of Class A common stock or equity awards issuable for an amount equal to 1% or more of the securities issuable pursuant to the Company's 2017 and 2019 Stock Option Plans: Christopher Barnum, Josh Schoonover and Cory Ellspermann.

**PLAN OF DISTRIBUTION**

**Timing of Sales**

The selling stockholders may offer and sell the shares covered by this reoffer prospectus at various times. The selling stockholders will act independently of our company in making decisions with respect to the timing, manner and size of each sale.

To our knowledge, no selling stockholder has any agreement or understanding, directly or indirectly, with any person to resell the shares of common stock covered by this reoffer prospectus.

**Offering Price**

The sales price offered by the selling stockholders to the public may be:

&nbsp;&nbsp;&nbsp;&nbsp;1. the
market price prevailing at the time of sale;

&nbsp;&nbsp;&nbsp;&nbsp;2. a
price related to such prevailing market price; or

&nbsp;&nbsp;&nbsp;&nbsp;3. such
other price as the selling stockholders determine from time to time.

**Manner of Sale** 

The shares of common stock may be sold by means of one or more of the following methods:

&nbsp;&nbsp;&nbsp;&nbsp;1. a
block trade in which the broker-dealer so engaged will attempt to sell the shares of common stock as agent, but may position and resell
a portion of the block as principal to facilitate the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;2. purchases
by a broker-dealer as principal and resale by that broker-dealer for its account pursuant to this reoffer prospectus;

&nbsp;&nbsp;&nbsp;&nbsp;3. ordinary
brokerage transactions in which the broker solicits purchasers;

&nbsp;&nbsp;&nbsp;&nbsp;4. through
options, swaps or derivatives;

&nbsp;&nbsp;&nbsp;&nbsp;5. in
transactions to cover short sales;

&nbsp;&nbsp;&nbsp;&nbsp;6. privately
negotiated transactions; or

&nbsp;&nbsp;&nbsp;&nbsp;7. in
a combination of any of the above methods.

The selling stockholders may sell their shares of common stock directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares of common stock. Brokers or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of shares of common stock, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved.

Broker-dealers may agree with a selling stockholder to sell a specified number of shares of common stock at a stipulated price per common share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares of common stock at the price required to fulfill the broker-dealer commitment to the selling stockholder.

Broker-dealers who acquire shares of common stock as principal may thereafter resell the shares of common stock from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, on the Nasdaq Capital Market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares of common stock, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

If the selling stockholders enter into arrangements with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing such arrangements, including the names of any broker-dealers acting as underwriters.

The selling stockholders and any broker-dealers or agents that participate with the selling stockholders in the sale of the shares of common stock may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

**Sales Pursuant to Rule 144**

Any shares of common stock covered by this reoffer prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant to this reoffer prospectus.

**Regulation M**

The selling stockholders must comply with the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act") in the offer and sale of the common stock. In particular we will advise the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares of common stock in the market and to the activities of the selling stockholders and their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the distribution.

Accordingly, during such times as a selling stockholder may be deemed to be engaged in a distribution of the common stock, and therefore be considered to be an underwriter, the selling stockholder must comply with applicable law and, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. may not engage in any stabilization activities in connection with our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. may not cover short sales by purchasing shares while the distribution is taking place; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.

In addition, we will make copies of this reoffer prospectus available to the selling stockholders for the purpose of satisfying the reoffer prospectus delivery requirements of the Securities Act.

**State Securities Laws**

Under the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from registration or qualification is available and is complied with.

**Expenses of Registration**

We are bearing all costs relating to the registration of the common stock. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection with any sale of the common stock.

**LEGAL MATTERS**

The validity of the common stock has been passed upon by Sichenzia Ross Ference Carmel LLP, New York, New York.

**EXPERTS**

The consolidated financial statements of INmune Bio Inc. as of and for the years ended December 31, 2024 and 2023 appearing in INmune Bio Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024, have been audited by Marcum LLP, as set forth in its report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**INCORPORATION OF CERTAIN DOCUMENTS by Reference**

The SEC, allows us to incorporate by reference certain of our publicly filed documents into this reoffer prospectus, which means that such information is considered part of this reoffer prospectus. Information that we file with the SEC subsequent to the date of this reoffer prospectus will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have sold all of the shares offered hereby or such shares have been deregistered.

● Our Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1711754/000101376225003354/ea0229965-10k_inmune.htm) for the year ended December 31, 2024, filed with the SEC on March 27, 2025;

● Our Quarterly Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711754/000121390025041072/ea0239166-10q_inmune.htm) for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025 ;

● Our Definitive Proxy Statement on Schedule 14A filed with the SEC on [April 21, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025033742/ea0237268-01.htm) , as supplemented on [April 25, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025035538/ea0239501-defa14a_inmune.htm) , and as amended on [May 9, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025041516/ea0241465-defr14a_inmune.htm) , respectively;

● our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on [January 28, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm) , [February 10, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea0230277-8k_inmune.htm) , [February 12, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm) , [March 24, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000101376225001309/ea0234771-8k_inmune.htm) , [April 1, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm) , [April 14, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm) , [May 5, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025039733/ea0240883-8k_inmune.htm) , [May 7, 2025,](https://www.sec.gov/Archives/edgar/data/1711754/000121390025040727/ea0241210-8k_inmune.htm) [May 14, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025043270/ea0242053-8k_inmune.htm) and [June 10, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm) and

● The description of our common stock contained in our Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm) filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a [Form 8-A](http://www.sec.gov/Archives/edgar/data/1711754/000121390020045474/ea132342-8a12b_inmune.htm) filed on December 30, 2020, contains a description of certain rights attributable to the common stock.

Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this Registration Statement. The information about us contained in this reoffer prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.

**Disclosure Of Commission Position On Indemnification For Securities Act Liabilities**

NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

Our Articles of Incorporation provides that every person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including attorney's fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their rights under this Article.

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Additional Information Available to You**

This prospectus is part of a Registration Statement on Form S-8 that we filed with the SEC. Certain information in the Registration Statement has been omitted from this prospectus in accordance with the rules of the SEC. We file annual, quarterly and special reports, proxy statements and other information with the SEC. You can inspect and copy the Registration Statement as well as reports, proxy statements and other information we have filed with the SEC at the public reference room maintained by the SEC at 100 F Street N.E. Washington, D.C. 20549, You can obtain copies from the public reference room of the SEC at 100 F Street N.E. Washington, D.C. 20549, upon payment of certain fees. You can call the SEC at 1-800-732-0330 for further information about the public reference room. We are also required to file electronic versions of these documents with the SEC, which may be accessed through the SEC's World Wide Web site at http://www.sec.gov. No dealer, salesperson or other person is authorized to give any information or to make any representations other than those contained in this prospectus, and, if given or made, such information or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to buy any security other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by any person in any jurisdiction where such offer or solicitation is not authorized or is unlawful. Neither delivery of this prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our company since the date hereof.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.**

The Securities and Exchange Commission, or SEC, allows us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information is considered part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have sold all of the shares offered hereby or such shares have been deregistered.

● Our Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1711754/000101376225003354/ea0229965-10k_inmune.htm) for the year ended December 31, 2024, filed with the SEC on March 27, 2025;

● Our Quarterly Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1711754/000121390025041072/ea0239166-10q_inmune.htm) for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025 ;

● Our Definitive Proxy Statement on Schedule 14A filed with the SEC on [April 21, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025033742/ea0237268-01.htm) , as supplemented on [April 25, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025035538/ea0239501-defa14a_inmune.htm) , and as amended on [May 9, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025041516/ea0241465-defr14a_inmune.htm) , respectively;

● our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on [January 28, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm) , [February 10, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea0230277-8k_inmune.htm) , [February 12, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm) , [March 24, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000101376225001309/ea0234771-8k_inmune.htm) , [April 1, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm) , [April 14, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm) , [May 5, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025039733/ea0240883-8k_inmune.htm) , [May 7, 2025,](https://www.sec.gov/Archives/edgar/data/1711754/000121390025040727/ea0241210-8k_inmune.htm) [May 14, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025043270/ea0242053-8k_inmune.htm) and [June 10, 2025](https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm) and

● The description of our common stock contained in our Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm) filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a [Form 8-A](http://www.sec.gov/Archives/edgar/data/1711754/000121390020045474/ea132342-8a12b_inmune.htm) filed on December 30, 2020, contains a description of certain rights attributable to the common stock.

Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this Registration Statement. The information about us contained in this reoffer prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

None.

**Item 6. Indemnification of Directors and Officers.**

Section 78.7502(1) of the Nevada Revised Statutes ("NRS") provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

Our Articles of Incorporation provides that very person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including attorney's fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their rights under this Article.

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).](http://www.sec.gov/Archives/edgar/data/1711754/000164033418001703/inmune_ex31.htm) |
| 4.2 | [Bylaws (Incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).](http://www.sec.gov/Archives/edgar/data/1711754/000164033418001703/inmune_ex32.htm) |
| 4.3 | [First Amendment to the Bylaws of INmune Bio Inc. (Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on May 23, 2024).](https://www.sec.gov/Archives/edgar/data/1711754/000121390024046252/ea020679101ex3-1_inmune.htm) |
| 5.1 | [Opinion of Sichenzia Ross Ference Carmel LLP\*](ea024481701ex5-1_inmune.htm) |
| 23.1 | [Consent of Marcum LLP\*](ea024481701ex23-1_inmune.htm) |
| 23.2 | [Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)\*](ea024481701ex5-1_inmune.htm) |
| 24.1 | [Power of Attorney (included on the signature page)\*](#poa_001) |
| 99.1 | [INmune Bio Inc. 2017 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).](http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528ex99-1_inmunebioinc.htm) |
| 99.2 | [INmune Bio Inc. 2019 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).](http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528ex99-2_inmunebioinc.htm) |
| 107 | [Filing Fee Table\*](http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528-s8_inmunebioinc.htm) |

---

\* Filed herewith.

\*\* Previously Filed.

**Item 9. Undertakings.**

(a) The
Company hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To
reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
material change to such information in the Registration Statement; provided, however, that (A) paragraphs (a)(1)(i) and (a)(1)(ii)
of this section do not apply if the Registration Statement is on Form S–8 (§239.16b of Regulation S-K), and the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities
and Exchange Commission by the Company pursuant to section 13 or section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are
incorporated by reference in the Registration Statement; and (B) paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if
the Registration Statement is on Form S-3 or Form F-3, and the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to Section 13
or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form
of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement; provided further, however, that paragraphs (a)(1)(i)
and (a)(1)(ii) do not apply if the Registration Statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and
the information required to be included in a post-effective amendment is provided pursuant to Item 1100(c) of Regulation AB.

&nbsp;&nbsp;&nbsp;&nbsp;(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;(4) That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Each prospectus filed by a Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(b) The
Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company's
annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration
Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or
paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 13, 2025.

---

| |
|:---|
| **INmune Bio Inc.**  |
| /s/ Raymond J. Tesi |
| Raymond J. Tesi, M. D. |
| Chief Executive Officer |
| (Principal Executive Officer) |
| /s/ David J. Moss |
| David J. Moss |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |

---

Each person whose signature appears below constitutes and appoints Raymond J. Tesi and David J. Moss, and each of them severally, as his true and lawful attorney in fact and agent, with full powers of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| /s/ Raymond J. Tesi | June 13, 2025 |
| Raymond J. Tesi, M.D. |  |
| Chief Executive Officer and Director<br> (principal executive officer) |  |
| /s/ David J. Moss | June 13, 2025 |
| David J. Moss |  |
| Chief Financial Officer<br> (principal financial and accounting officer) |  |
| /s/ Timothy Schroeder | June 13, 2025 |
| Timothy Schroeder |  |
| Director |  |
| /s/ J. Kelly Ganjei | June 13, 2025 |
| J. Kelly Ganjei |  |
| Director |  |
| /s/ Scott Juda | June 13, 2025 |
| Scott Juda, JD |  |
| Director |  |
| /s/ Marcia Allen | June 13, 2025 |
| Marcia Allen |  |
| Director |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

---

| | |
|:---|:---|
| ***VIA ELECTRONIC TRANSMISSION*** | June 13, 2025 |

---

INmune Bio Inc.

225 NE Mizner Blvd., Suite 640

Boca Raton, Florida 33432

Re: Post-Effective Amendment No. 2 to:

Registration Statement on Form S-8 No. 333-254577

Ladies and Gentlemen:

We refer to the above-captioned post-effective amendment no. 2 to the registration statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Act"), being filed by INmune Bio Inc., a Nevada corporation (the "Company"), with the Securities and Exchange Commission.

We have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents.

Based on our examination mentioned above, we are of the opinion that the shares of common stock being issued pursuant to the Registration Statement, will be, when so issued, duly authorized, legally and validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving the foregoing consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Securities and Exchange Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ *Sichenzia Ross Ference Carmel LLP* |
| Sichenzia Ross Ference Carmel LLP |

---

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 23.1

**Exhibit 23.1**

<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 27, 2025 with respect to the financial statements of INmune Bio Inc. for the year ended December 31, 2024 included in the Annual Report on Form 10-K. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Marcum LLP

Houston, Texas

June 13, 2025

## Ex-Filing

**Exhibit 107**

Calculation of Filing Fee Table

Form S-8

(Form Type)

INmune Bio Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1 - Newly Registered Securities</u>

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered <sup>(1)</sup> |  | Proposed Maximum Offering Price Per Share |  | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | Common Stock, par value $0001 per share | Rule 457(h) | **3324550** | **(2)** | $8.05 | (3) | $26762628 | $0.0001531 | $4098 |
|  | **Total Offering Amounts** |  |  |  |  |  |  | $— | $— |
|  | **Total Fee Offsets<sup>(4)</sup>** |  |  |  |  |  |  |  |  |
|  | **Net Fee Due** |  |  |  |  |  |  |  | $4098 |

---

(1) Pursuant to Rule 416(a) under the
 Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional
 shares of the Registrant's common stock that become issuable in respect of the securities identified in the above
 table by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the receipt of
 consideration that increases the number of the Registrant's outstanding shares of common stock.

(2) Represents shares of common stock issuable upon equity awards from the Registrant's 2017 and/or 2019 Stock k Incentive Plan issued to certain employees of the registrant upon exercise of stock option awards.

(3) Estimated in accordance with Rule 457(h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $8.05 per share, which is the average of the high and low prices of the Registrant's Common Stock on June 11, 2025, as reported on The Nasdaq Capital Market.

(4) The Registrant has no fee offsets.